Antiangiogenic gene transfer has the potential to be more efficacious than protein-based therapies or pharmacotherapies for the control of solid tumor growth, invasion and metastasis. For a sustained antiangiogenic effect, a vector capable of long-term expression without vector-associated immunity or toxicity is advantageous. The present study evaluated the potential of a recombinant adeno-associated virus-2 (rAAV) encoding the human soluble FMS-like tyrosine kinase receptor 1 (sFlt-1), which functions by both sequestering vascular endothelial growth factor (VEGF) and forming inactive heterodimers with other membranespanning VEGF receptors, in vitro and in vivo. Results indicated significant growth inhibitory activity of the transgenic factor in a human umbilical vein endothelial cell proliferation assay in vitro and protection against the growth of an angiogenesis-dependent human ovarian cancer cell line, SKOV3.ip1, xenograft in vivo with increased disease-free survival. Stable expression of the secretory factor and transgene persistence were confirmed by immunohistochemistry and in situ hybridization analyses, respectively. Increased therapeutic effects on both the growth index of the implanted tumor cells and tumor-free survival also correlated with an increasing dose of the vector used. These studies indicate that rAAV-mediated sFlt-1 gene therapy may be a feasible approach for inhibiting tumor angiogenesis, particularly as an adjuvant/therapy.
A better understanding of the interaction of normal host and tumor cells has provided clues towards developing novel therapies for cancer. Cancer gene therapy targeting non-neoplastic cells has recently shown greater potential against tumor growth and metastasis in preclinical models. One of the promising areas of cancer therapy is targeting the growth of tumor-associated endothelium, which provides anchorage and nourishment for the growth of solid tumors through the process of angiogenesis. 1 It has been clearly established that in the absence of angiogenesis, tumors fail to grow beyond 2-3 mm 3 in size and remain dormant. 1, 2 Thus, by providing antiangiogenic signals through sustained systemic expression of the inhibitory factors at therapeutic levels, it may be possible to control the growth of solid tumors.
Further, antiangiogenic gene therapy can be combined with conventional therapies such as radiation or chemotherapy or newer therapies including immunotherapy for synergistic effects. 3 For sustained expression of antiangiogenic factors at a therapeutic level by gene transfer, an important requirement is the use of vectors capable of stable expression without the possibility of elimination of transgenepositive cells by T-cell-mediated cytolysis. Adeno-associated virus (AAV)-based vectors have shown the potential for long-term expression of therapeutic genes without such vector-associated immunity or toxicity. [4] [5] [6] [7] Since antiangiogenic gene therapy mandates a sustained expression of the antiangiogenic factors at a therapeutic level, recombinant(r) AAV is an ideal vector to accomplish this.
Soluble FMS-like tyrosine kinase receptor 1 (sFlt-1) is a splice variant of the vascular endothelial growth factor (VEGF) receptor Flt-1, lacking the transmembrane and cytoplasmic domains. 8 VEGF is a potent angiogenic factor, and overexpression of VEGF has been reported to be associated with poor prognosis in many human cancers. [9] [10] [11] [12] [13] The VEGF antagonistic activity of sFlt-1 is effected both by forming inactive heterodimers with membrane-spanning VEGF receptor and by sequestering VEGF in a dominant-negative manner, thereby inhibiting the downstream VEGF signaling cascade following receptor-mediated internalization. 8 Thus, use of sFlt-1 for downregulating VEGF signaling at two different steps would maximize the process of inhibiting tumor neovascularization and associated tumor growth. The present study demonstrates that stable expression of sFlt-1 following rAAV-mediated gene transfer provides significant protection against the growth of an angiogenesisdependent human ovarian cancer cell line in a mouse xenograft model suggesting its potential application in antiangiogenic cancer gene therapy in human beings.
Materials and methods

Cells and reagents
The human embryonic kidney cell line, 293, was purchased from the ATCC and maintained in Iscove's modified essential medium supplemented with 10% fetal bovine serum. Human ovarian cancer cell line SKOV3.ip1 was a kind gift of Dr Janet Price (MD Anderson Cancer Center, Houston, TX) and was maintained as before. 14 Primary human umbilical vein endothelial cells (HUVEC) were obtained from Dr Francoise Booyse (The University of Alabama at Birmingham, AL) and maintained as before. 15 Restriction endonucelases and other modifying enzymes were purchased from either New England Biolabs (Beverly, MA) or Promega Corporation (Madison, WI). A mouse monoclonal anti-human VEGF receptor-1 (Flt-1 receptor) antibody, which recognizes the extracellular domain of Flt-1 (represented in the sFlt-1) was purchased from Sigma Chemicals (V4262, St Louis, MO). A rat anti-mouse monoclonal antibody for CD31 (PECAM-1) was purchased from Chemicon International (CBL1337, Temecula, CA). Secondary antibodies and color reagents were purchased from Abcam Inc. (Cambridge, MA) and Amersham (Piscataway, NJ). Purified recombinant human sFlt-1 was purchased from R&D Systems Inc. (Minneapolis, MN).
Construction of recombinant plasmids, production and purification of rAAV
All rAAV plasmids were constructed using pSub201 as the backbone. 16 cDNA encoding human sFlt-1 was cloned from a human placental cDNA library as described. 17 The coding sequences were initially subcloned in a mammalian expression vector pCI (Promega, Madison, WI) under the control of the CMV promoter and a cassette comprising the CMV promoter, sFlt-1 gene and polyadenylation signal sequence was isolated and subcloned in pSub201, replacing the AAV-2 genes. Packaging of rAAV-sFlt-1 was accomplished in an adenovirus-free system as described. 18 Purification of the virions was carried out in a discontinuous iodixanol gradient centrifugation followed by affinity purification in heparin affinity column. The particle titer of the purified virions was determined by quantitative slot blot analysis as described. 19, 20 Western blot analysis Western blot analysis was performed using conditioned media obtained from rAAV-transduced 293 cells. Briefly, conditioned media collected following mock-transduction (without any vector) or rAAV-sFlt-1 transduction was concentrated five-fold and 20 ml from each aliquot was electrophoretically separated in a 10% sodium dodecylsulfate polyacrylamide gel (SDS-PAGE). The gel was transferred to a PVDF membrane and immunodetection of the proteins was performed using a monoclonal antibody directed against the extracellular region of the human sFlt-1. A goat anti-mouse secondary antibody, conjugated to horseradish peroxidase (HRP), was used as a secondary antibody. Detection of the bands was performed using an enhanced chemiluminescent (ECL) system as described. 21 
Endothelial cell proliferation assay
Early passage HUVEC were seeded in gelatin-coated 96-well tissue culture plates at a density of 5 Â 10 3 cells per well and grown in EGM-2 medium containing hydrocortisone, human FGF-b, VEGF, ascorbic acid, heparin, human EGF and 10% fetal bovine serum (Clonetics Corp., San Diego, CA). After 24 hours, the medium was changed and 100 ml of fresh medium containing the same additive plus 20 ml of conditioned medium obtained from 293 cells that were either mock-transduced or transduced with 100 multiplicities of infection (MOI) of rAAV-sFlt-1. As a positive control, purified recombinant human angiostatin (R&D Systems, Minneapolis, MN) was added in a separate well at a concentration of 20 mg/ml. After 72 hours, the cells were fixed in 10% buffered-formalin and stained with 1% crystal violet in 70% ethanol as described 22 to analyze the rate of proliferation.
In vivo studies
Female athymic nude mice, 6 weeks old, were purchased from the Fredericks Cancer Institute, NCI, and housed in the animal facility of the University of Alabama at Birmingham (UAB). The animals were maintained following the Guidelines of the Institutional Animal Care and Use Committee (IACUC) after all experimental procedures were approved by both the UAB-IACUC and the Occupational Health and Safety Department. The animals were divided into six groups consisting of six mice per group. A total of 3 Â 10 11 particles of rAAV encoding either GFP, or sFlt-1, suspended in normal saline, were injected in a volume of 50-100 ml in the quadriceps muscle of the hind limb. Naı¨ve animals did not receive any vector. At 3 weeks after vector administration, each mouse was implanted with 10 7 SKOV3.ip1 cells, subcutaneously. A total of two injections were delivered per mouse, one in each flank. Tumor size was measured twice a week with a digital caliper for two-dimensional longest 3 , the animals were euthanized. The surviving mice were killed by the end of 130 days after tumor cell implantation, and the experiment terminated. At the time of killing either due to tumor burden or termination of the experiment, both the liver and regions of the quadriceps muscle at the site of sham or vector injection were isolated and processed for total DNA isolation, histology, immunohistochemistry and in situ hybridization.
Histological analyses of liver tissue
Liver tissues were harvested from naı¨ve or rAAV-sFlt1-treated mice. The tissues were immediately fixed in 10% buffered-formalin (pH 7.0) and embedded in paraffin following standard processing methods. Sections of 5 mm thickness were cut, deparaffinized in xylene and dehydrated in alcohol. The slides were hematoxylin and eosin (H&E) stained and mounted with cover slips. Analysis of the stained sections was carried out by a senior histopathologist by standard bright-field microscopy. 23 
PCR analysis for vector genome
Total DNA was isolated from naı¨ve or rAAV-sFlt1 administered mouse muscle using TRIizol reagent (GIB-CO-BRL). PCR amplification was carried out in a 30-cycle reaction using a primer-pair, specific for the amplification of the vector genome. The forward primer consisted sequence of CMV promoter and the reverse primer that of the human sFlt-1. The primer sequences were: forward primer 5 0 -TAAGCAGAGCTCGTT TAGTGAACCGT-3 0 and reverse primer, 5 0 -TACTCAC CATTTCAGGCAAAGACCAT-3 0 . The amplified product (548 bp) was electrophoretically separated on 1% agarose gels and the bands visualized by ethidium bromide staining.
Immunohistochemistry
The quadriceps muscle of mice were harvested under anesthesia and fixed immediately in alcoholic-formalin (PenFix; Richard-Allan, Kalamazoo, MI) for 18 hours at room temperature. The tissues were dehydrated in graded alcohol and embedded in paraffin. Sections of 5 mm thickness prepared on glass slides were deparaffinized in xylene and rehydrated via ethanol and placed in PBS. Antigen retrieval was performed by boiling the sections for 10 minutes in 0.01 M citrate buffer (pH 6.0) in a microwave oven. All sections were pretreated with a 3% aqueous solution of H 2 O 2 for 5 minutes to quench endogenous peroxidase. Sections were then treated with 3% goat serum for 1 hour at room temperature to reduce nonspecific staining followed by 1 hour incubation with a human monoclonal anti-VEGF receptor-1 antibody, which recognizes the extracellular domain of the human VEGF receptor-1 (present in the sFlt-1). The antibody was used at a concentration of 10 mg/ml. The remainder of staining procedure was performed using a Universal Mouse Kit (Biogenex, Sam Ramon, CA), which contained biotinylated goat linking antibody to mouse immunoglobulins and an HRP-streptavidin complex. Diaminobenzidine tetrahydrochloride (DAB) was used as a substrate for the visualization of antigen-antibody complex. Slides were minimally counterstained with hematoxylin. To determine the degree of neovasculature, tumor tissues from naı¨ve and rAAV-sFlt-1-treated mice, harvested at the same time, were processed as above. Detection of blood vessel was performed with a rat antimouse CD31 monoclonal antibody at a concentration of 10 mg/ml. The number and area of blood vessels in each group were counted in at least 10 different areas in a double-blinded method.
In situ hybridization
A digoxigenin (DIG)-labeled DNA probe containing the CMV promoter sequence was generated by PCR using the PCR-DIG labeling mix Plus (Roche Molecular Diagnostics) following the manufacturer's protocol. Formalinfixed tissues were sectioned to 5 mm thickness, deparaffinized in xylene and rehydrated through a series of gradedethanol and PBS. Slides were then treated with 0.01 M citrate buffer, pH 6.0 at 421C for 3 hours. Prehybridization was performed at 651C for 2 hours in hybridization solution (ULTRAhyb TM , Ambion, TX). The hybridization reaction was carried out with approximately 400 ng/ ml of the DIG-labeled DNA probe at 651C overnight. After thoroughly washing the excess probe, immunohistochemical detection of hybridization signals was performed using the DIG nucleic acid detection kit (Roche Molecular Diagnostics, Indianapolis, IN). Counterstaining of the slides was carried out with a diluted eosin solution for 1-2 minutes and then mounted with Crystal/ Mount (Biomeda, Forest City, CA).
Statistical analyses
The association of the presence or absence of tumor with differing treatment conditions was tested for statistical significance by using the w 2 -test. The distribution of the tumor volume was measured against a normal (Poisson's distribution) following log transformation. In a general linear mixed model of the data, the dependent variable was the logged tumor volume and the predictors were treatment, day after treatment and ''an interaction event'' between treatment and day 0. All three were subsequently shown to be statistically significant predictors. The values of blood vessel area from naı¨ve and rAAV-sFlt-1 were compared using the Student's t-test. P-values o.05 were considered to indicate significant difference between data sets.
Results
Generation of high-titer rAAV encoding human sFlt-1 for skeletal muscle injection
Previous studies have established sustained expression of rAAV transgenes in skeletal muscle without diminution of expression or deterioration of transgene-expressing cells by cytolytic T cells. Hence, in the present study, we have chosen skeletal muscle as a platform for rAAV administration and production of sFlt-1 as a secretory protein.
The human sFlt-1 cDNA was isolated from a HUVEC cDNA library 17 and subcloned in an rAAV vector under the control of the human cytomegalovirus immediate early promoter (CMV) (Fig 1) . The rAAV was packaged in a helper virus-free system and purified using discontinuous iodixanol gradient centrifugation and affinity chromatography. The titer of the vector ranged between 1 Â 10 12 and 5 Â 10 12 particles/ml.
Determination of sFlt-1 expression as a secretory protein
The rAAV-sFlt-1 was tested in 293 cells for the extracellular secretion of the factor. Since the cDNA of cloned sFlt-1 contained the native VEGF receptor secretory signal, no additional modifications were performed to achieve extracellular transport of sFlt-1 from the transduced cells. The cells were either mock-transduced or transduced with 100 MOI of the rAAV encoding sFlt-1. The conditioned medium, obtained 48 hours after transduction, was concentrated five-fold and separated on SDS-PAGE and Western blot analysis performed using a monoclonal antibody, which recognizes human sFlt-1. Determination of biological activity of sFlt-1 following rAAV transduction
In the next set of experiments, we determined the biological activity of rAAV-expressed sFlt-1. We based our therapeutic approach on the well-established property of rAAV transgene expression as a secretory protein in skeletal muscle. Thus, the in vitro evaluation of the biological activity was performed mimicking the in vivo strategy. The rAAV-containing sFlt-1 gene was transduced into 293 cells and the transgene product was obtained as a secreted protein in the supernatant. The supernatant was added to early passage HUVEC, grown in the presence of 10 ng/ml VEGF. After 72 hours, the cells were fixed and stained with crystal violet. The proliferation index was determined by microphotography. Results, given in Figure 3 , indicated a significant inhibition of HUVEC proliferation following the addition of supernatant from rAAV-sFlt1 transduced cells but not from the mock-transduced cells. As a positive control, purified recombinant human angiostatin was used at a concentration of 20 mg/ml, which also showed a significant inhibition of HUVEC proliferation. Highest inhibition, comparable to that from purified angiostatin, was observed with 25 ml supernatant indicating that an amount of approximately 125 ng/ml is produced in the supernatant of rAAV-sFlt-1-transduced cells.
Development of a xenograft tumor model and vector treatment
As a model system to evaluate the in vivo antiangiogenic effects of rAAV-mediated long-term expression of sFlt-1, we developed subcutaneous tumors with an angiogenesisdependent human ovarian cancer cell line SKOV3.ip1. Our pilot studies indicated that palpable tumors begin to appear 8-10 days following subcutaneous implantation of 10 7 SKOV3.ip1 cells in nude mice (data not shown). Since we based the present studies to evaluate the potential of AAV-mediated sFlt-1 gene therapy as a possible preventive therapy against the growth and recurrence of solid tumors, the animals were first injected with rAAV encoding sFlt-1. Also because optimal expression of rAAV transgenes is not achieved until at least 2 weeks after vector administration, tumor challenge was performed 3 weeks after vector administration. Each animal received an injection in both flanks. All the naı¨ve animals and rAAV-GFP administered animals developed palpable tumors by 8 days after injection. The animals that developed tumors were monitored until the tumor volume reached 1800 mm 3 and euthanized according to the IACUC approved guidelines. Tumor-free animals were monitored for 130 days before terminating the experiment. 
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Evidence of transgene persistence and expression following rAAV-sFlt-1 therapy in vivo A major advantage of using rAAV in muscle-based gene therapy is the stable retention of transgene(s) for longterm expression. Since antiangiogenic gene therapy is directed towards inhibiting proliferation of tumor neovasculature and not tumor cells directly, an important requirement for antiangiogenic therapy is stable expression of these factors at therapeutic levels. Studies have reported that administration of rAAV in muscle not only results in long-term expression of the transgene but also that vector administered in this way does not elicit any host immune response against the transgenic protein, which would otherwise eliminate transgene-expressing cells. 4, 24 Thus, in the present study, we sought to achieve this result by using skeletal muscle as a target tissue for transduction of rAAV and systemic secretion of sFlt-1. To demonstrate the long-term persistence of the AAV transgene, we performed genomic PCR and in situ hybridization, and to determine the systemic secretion of sFlt-1 from transduced muscle, we performed immunohistochemistry.
PCR analysis of vector genome was performed using total DNA isolated from naı¨ve or rAAV-sFlt-1 treated mouse muscle. The forward and reverse primers consisted sequences of CMV promoter and human sFlt-1 coding sequences respectively. An amplification product of 548 bp, only in rAAV-sFlt-1 treated mice (Fig 4(i) ) confirmed the persistence of vector genome. For in situ hybridization analysis, we used a digoxigenin (DIG)-labeled CMV promoter sequence as the probe. Results, shown in Figure 4 (iii), also demonstrate the persistence of the AAV transgene in the skeletal muscle of only the vector-treated mice after 130 days. The use of CMVpromoter sequence as a probe in the in situ hybridization experiment also eliminated the possibility of hybridization signal from transgenic mRNA transcripts as well as cellular Flt-1 genomic DNA. Although the results of PCR or in situ hybridization do not confirm the integration of the rAAV genome into the host, increasing evidence indicate that only a small amount of rAAV transgenes integrate in vivo. 25 Nonetheless, in skeletal muscle, concatemerization of the rAAV genome allows long-term retention of transgenes as circular episomes. 6, 7 Immunohistochemistry was performed in paraffin sections of the transduced muscle and tumor tissues from naı¨ve and rAAV-sFlt-1-treated mice to determine the expression of human sFlt-1 and degree of neovasculature respectively. Data, shown in Figure 4b , indicates systemic secretion of human sFlt-1 from the quadriceps muscle, only from rAAV-sFlt1-treated mice. Since the present study was performed as a preventive approach, tumor growth was not observed in disease-free animals in the sFlt-1 group. However, when the tumor sections were stained with CD31 antibody, there was a significant decrease (Po.04) in the blood vessel area in rAAV-sFlt-1 group suggesting the inhibitory effect on blood vessel growth.
Stable expression of sFlt-1 inhibits tumor growth in vivo
The results of the in vivo studies on growth kinetics of SKOV3.ip1 cells and tumor-free survival with a vector dose of 3 Â 10 11 particles are given in Figures 5 and 6 , respectively. However, when a vector dose of 3 Â 10 10 particles was used, although there was a modest increase in tumor-free survival and a lesser mean tumor volume was noted, these effects were not statistically significant (data not shown). Palpable tumors started to develop 8 days after tumor challenge in naı¨ve animals. When a dose a b c Figure 3 Endothelial cell proliferation assay to determine the biological activity of rAAV-sFlt-1. rAAV encoding sFlt-1 was transduced into 293 cells at an MOI of 100. After 48 hours, 25 ml of supernatant from mock-transduced (a) or rAAV-sFlt-1transduced (b) cells was tested on HUVEC. Cell proliferation was determined by fixing and staining the HUVEC with crystal violet. Purified recombinant human angiostatin was used at a concentration of 20 mg/ml (c) as a positive control. Magnification Â 20.
AAV2-mediated sFlt-1 cancer gene therapy G Mahendra et al of 3 Â 10 10 particles of rAAV-sFlt1 was given, tumor-free survival was seen in 433% of the animals (P4.05) whereas a dose of 3 Â 10 11 particles protected 83% of the mice (Po.005). At a higher vector dose, there was also a significant difference in the mean tumor volume between different treatments (naı¨ve or GFP versus sFlt-1, Po.0001). There was a slight delay in the appearance of tumors in the rAAV-GFP-treated group compared to naı¨ve animals, which did not receive any vector.
rAAV-sFlt-1 therapy does not cause liver damage
Previous studies have indicated that higher levels of sFlt-1 in mouse liver cause significant hepatotoxicity associated with hemorrhage of blood vessels in the liver.
14 VEGF has been reported to regulate the proliferation and survival of the sinusoidal endothelial cells acting through the VEGF receptors Flt-1 and Flk-1. 26, 27 Blockade of the receptors, resulting from higher concentrations of sFlt-1 leads to such damage. Thus, overexpression of sFlt-1 from systemically delivered adenovirus vector, which targets liver, has been reported to result in similar damage.
14 To determine if stable systemic expression of sFlt-1 by rAAV leads to liver toxicity, liver tissues were macroscopically and microscopically examined following rAAV-sFlt-1 treatment. H&E-stained sections from naı¨ve and AAVsFlt-1-treated mice showed no cytomorphological signs of hepatotoxicity strongly suggesting that systemic expression of sFlt-1 from skeletal muscle does not result in liver toxicity (Fig 7) . Further, immunohistochemical staining for human sFlt-1 in the liver sections did not reveal accumulation of systemically expressed sFlt-1 (data not shown) indicating that delivery of rAAV-sFlt-1 in skeletal muscle and systemic secretion of the factor at stable levels would be advantageous. Also, several studies using rAAV encoding a variety of therapeutic proteins have shown stable systemic expression of transgenic factors following intramuscular vector administration. No apparent effects such as loss of body weight, general mobility or food uptake was observed in the rAAV-sFlt-1-treated mice compared to untreated mice that were not tumor challenged. PCR was performed using genomic DNA isolated from naïve or rAAV-sFlt-1-injected muscle using a primer-pair specific for the amplification of the transgene. Whereas no amplification product was seen in DNA from naïve mice (lanes 1 and 2), a 548 bp fragment, specific for the transgene, was amplified from rAAV-sFlt-1-treated mice (lanes 3 and 4, (i)). Sham-or rAAV-transduced muscle tissues were harvested and immediately fixed in buffered-formalin for 24 hours and then embedded in paraffin. In situ hybridization was performed using a DIG-labeled DNA probe on sections obtained from naïve (ii), or rAAV-sFlt1 (iii) administered muscle tissues. A two-fold magnification of a specific area is indicated in the box, showing positive signal only in the vector-transduced group. Bottom panel: Immunohistochemistry was performed using a human VEGF receptor-1 antibody, which recognizes the extracellular domain of VEGF receptor. Extracellular secretion of the transgenic factor from the vector-transduced muscle tissue is evident in rAAV-sFlt1 treated animal (b) compared to naïve mouse (a). Days Percent survival Figure 6 Tumor-free survival of mice following rAAV-sFlt-1 therapy. A total of 3 Â 10 11 particles of rAAV encoding GFP, or sFlt1 were injected into the quadriceps muscle in the hindlimb of athymic nude mice. At 3 weeks after the vector injection, the animals were challenged with 10 7 SKOV3.ip1 cells in each flank subcutaneously and tumor-free survival recorded. The mean tumor-free survival of naïve (E), rAAV-GFP (&), or rAAV-sFlt1 (m) is given above.
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Discussion
Recent studies have indicated the potential of sFlt-1 gene therapy in murine models of human diseases using viral vectors. 15, [28] [29] [30] [31] [32] Whereas studies using adenoviral and retroviral vectors have reported the efficacy of sFlt-1 gene therapy in inhibiting the growth of human tumors, that using AAV reported the effects in retinal diseases and in vivo growth of a stably transduced cell line. 31, 32 The present study demonstrates that stable expression of sFlt-1 as a secretory protein from skeletal muscle by rAAV provides significant protection and long-term survival of mice against the growth of a human tumor xenograft suggesting its potential in cancer gene therapy.
The potential use of rAAV-sFlt1 as a vector for antiangiogenic therapy of solid tumors is multifold. Since tumor angiogenesis is mediated by a cascade of signals provided by cells of both tumor and endothelial origin, which ultimately results in the growth and differentiation of endothelial cells forming the tumor neovasculature, therapy targeting such an event should be sustained to effect a maximal tumoristatic response. Stable expression of transgenic factors as secretory proteins by administering rAAV in skeletal muscle has been well established in preclinical models 6, 7, [33] [34] [35] [36] [37] and formed the basis for a human clinical trial. 38 Thus, the proven efficiency of muscle-based administration of rAAV-sFlt-1 should provide sustained antiangiogenic effects. Since sFlt-1 is a native protein, there is no expected host immune response against the transgenic factor when used for therapy in humans. Further, the cytolytic T-cell response against rAAV-transduced muscle is known to be minimal due to both low-immunogenicity against the vector and poor transduction of rAAV to dendritic cells. 24 Thus, the potential of muscle-based rAAV-sFlt-1 therapy should be advantageous. Although several drugs have shown promise in controlling tumor neovasculature, a major problem in pharmacotherapy is the profound side effects of constant administration due to their limited half-life. 39 Gene therapy, on the other hand, offers advantages of maximizing cost effectiveness while maintaining sustained levels of antiangiogenic factors. Although many factors are known to play important roles in new blood vessel formation, a key molecule promoting the growth of tumor neovasculature is VEGF, which has been considered a predictive marker in many human cancers. [9] [10] [11] [12] [13] Further, overexpression of VEGF mRNA and elevated serum VEGF levels have been correlated with decreased survival in many neoplastic conditions including ovarian cancer. 40 Despite higher levels of plasma VEGF levels observed in many human cancers, there was no concomitant increase in sFlt-1 levels in cancer patients indicating an imbalance in the native antiangiogenic signal pathway. 41 In patients who showed earlier relapse of breast cancer, tumor VEGF levels were higher than in patients with a longer disease-free survival and the rate of response to chemotherapy decreased with higher VEGF levels. 42 Hence, a stable gene therapy approach targeting VEGF as an adjuvant therapy offers the promise of increased survival in patients.
Inhibition of endogenous VEGF levels by the administration of VEGF antibody alone or in combination of topoisomerase inhibitors has resulted in effective immunotherapy and reduction of Wilms' tumor respectively in murine models. 43, 44 Unlike other biologically driven antiangiogenic factors such as angiostatin and endostatin whose mechanism of action are not fully elucidated despite their antiangiogenic effects, the biological properties of sFlt-1 are well known. The sFlt-1 acts by both sequestering VEGF and blocking VEGF receptors from binding to VEGF. 8 Thus, therapy targeting VEGF will have specific effects on tumor growth inhibition and metastasis.
We have recently reported that intravenous administration of adenovirus encoding sFlt-1 results in systemic toxicity due to high sFlt-1 expression in liver.
14 By using an adenovirus encoding GFP, the toxicity was determined to be due to increased sFlt-1 levels rather than vector localization in liver. Thus, using skeletal muscle as a platform to achieve systemically therapeutic levels of sFlt-1, rAAV can overcome such a deleterious effect in addition to offering the advantage of long-term expression. In a recent preclinical study, we also demonstrated that significant inhibition of tumor growth can be achieved by intramuscular administration of rAAV encoding angiostatin and endostatin as secretory proteins. 45 Histopathological analysis of liver from rAAVsFlt-1 treated mice liver also confirmed the absence of any cytomorphic damage.
Results of our studies additionally indicated that significant therapeutic effect was seen only with a vector dose of 3 Â 10 11 particles in mice. Thus, a clinical translation of these findings would require careful determination of optimal vector dose. Although we did a b Figure 7 Absence of hepatotoxicity following rAAV-sFlt-1 therapy.
Livers from naïve or rAAV-sFlt-1-treated mice were formalin-fixed, sectioned to 5 mm thickness and stained with H&E. The stained slides were analyzed by light microscopy for hepatotoxicity including hemorrhage and congestion, focal necrosis with minimal inflammation, hepatocyte dropout, or increased apoptosis. There was no difference that existed in the histopathology of liver sections between naïve mice (a) and rAAV-sFlt1-treated mice (b).
AAV2-mediated sFlt-1 cancer gene therapy G Mahendra et al not quantitatively determine the systemic levels of sFlt-1 following therapy, at the therapeutically efficacious dose, immunohistochemical analysis of rAAV-sFlt-1 injected muscle and adjacent blood vessels clearly indicated abundant expression and secretion of sFlt-1, suggesting that delivery of the sFlt-1 transgene in muscle is a safer method of overcoming any potential toxicity due to systemic delivery of a recombinant adenovirus encoding sFlt-1. A recent study on the potential use of rAAV encoding sFlt-1 in ovarian cancer reported that transduction of the human ovarian cancer cell line, RMG-1, with AAV-sFlt1 in vitro followed by intraperitoneal administration in nude mice resulted in a decrease in proliferative and metastatic indices, further suggesting the feasibility of localized AAV-sFlt-1 antiangiogenic gene therapy. 32 However, a major limitation of intratumoral delivery is the limited transduction efficiency and dispersion of the vector within the tumor cells. Also, unlike certain genetic metabolic diseases, which require only partial amounts of the deficient protein/enzyme for phenotypic correction of the disease, tumor therapy requires inhibition of the tumor growth in toto. Antiangiogenic therapy, in particular, requires a constant level of the inhibitory factor(s) for a sustained therapeutic effect. Thus, the strategy that we adapted in the present study will likely have greater potential and translational utility for human cancers, in particular, as an adjuvant therapy against tumor recurrence. Although several preclinical studies have shown that stable levels of systemically secreted proteins using rAAV resulted in the phenotypic correction of inherited metabolic defects, 6, 7 accumulation of antiangiogenic factors in other organs due to unregulated expression may lead to ischemic conditions or impair wound healing. Thus, future studies are warranted to test the efficacy of regulated expression of these factors by using inducible promoters 46, 47 for a safe muscle-based rAAV antiangiogenic gene therapy.
